All In Biotech

Free tool

FAERS Monitor: Atropine Sulfate

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213581 or its brand name (Atropine Sulfate, Atropine Sulfate). Reports on generic versions are filed under their own applications.

Reports

2,540

Serious

2,136

84% of reports

Hospitalization

969

Death reported

398

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective315
  • off label use211
  • macular degeneration199
  • nausea193
  • pyrexia161
  • diarrhoea149
  • pain136
  • malaise132
  • headache129
  • weight decreased120
  • death118
  • constipation115
  • erythema109
  • vomiting105
  • abdominal pain103

Reports by year received

View as table
YearReports
200455
200562
200650
200755
200872
200945
201075
201167
201271
201360
201467
201574
2016112
201790
2018122
2019181
2020158
2021146
2022226
2023231
2024232
2025185
2026103

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,619 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
macular degenerationSignal199140.3122.626,940
erythemaSignal1094.43.7285
constipationSignal1154.43.7298
pyrexiaSignal1613.93.3343
abdominal painSignal1033.73.0199
weight decreasedSignal1203.63.0221
malaiseSignal1322.52.1119
nauseaSignal1932.01.8102
off label use2112.01.8108
drug ineffective3152.01.8162
diarrhoea1491.91.666
vomiting1051.81.541
pain1361.81.652
headache1291.71.438
death1181.11.02

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.